Shares of Galapagos NV (GLPG) , a clinical-stage company, are rising in the premarket hours on Aug 23, after the FDA cleared its investigational new drug application to begin an early to mid-stage study of GLPG5101 in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). GLPG5101 is an autologous CD19 CAR-T cell therapy product candidate, which is administered as a single, fixed, intravenous dose. It has been developed utilizing Galapagos' proprietary decentralized cell therapy manufacturing pla ...